A Comparison of AmBisome® to Amphotericin B for Treatment of Systemic Candidiasis in Very Low Birth Weight Infants
Open Access
- 1 January 2007
- journal article
- clinical trial
- Published by XMLink in Yonsei Medical Journal
- Vol. 48 (4) , 619-626
Abstract
Jeon GW, et al. Yonsei Med J. 2007 Aug;48(4):619-626. http://dx.doi.org/10.3349/ymj.2007.48.4.619Keywords
This publication has 23 references indexed in Scilit:
- Changing Incidence ofCandidaBloodstream Infections Among NICU Patients in the United States: 1995–2004Pediatrics, 2006
- Candidemia in Neonatal Intensive Care UnitsThe Pediatric Infectious Disease Journal, 2006
- Neonatal Candidiasis Among Extremely Low Birth Weight Infants: Risk Factors, Mortality Rates, and Neurodevelopmental Outcomes at 18 to 22 MonthsPediatrics, 2006
- The efficacy of two different lipid‐based amphotericin B in neonatal Candida septicemiaPediatrics International, 2005
- Breakthrough Candida Infection in a Preterm Infant with Congenital CutaneousCandida albicansInfectionAmerican Journal of Perinatology, 2005
- Treatment of candidaemia in premature infants: comparison of three amphotericin B preparationsJournal of Antimicrobial Chemotherapy, 2003
- Amphotericin B-induced hepatorenal failure in cystic fibrosisPediatric Pulmonology, 2002
- AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experienceJournal of Antimicrobial Chemotherapy, 2002
- Introduction to Antifungal DrugsClinical Infectious Diseases, 2000
- Renal Function in Preterm NeonatesPediatric Research, 1994